基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
转移性化生性乳腺癌患者接受免疫检查点抑制剂联合化疗后获得持久完全缓解：一例病例报告及文献复习
英文原题：Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature.
查看英文原题
Long-Lasting Complete Remission in a Patient With Metastatic Metaplastic Breast Cancer Treated With Immune Checkpoint Inhibitor and Chemotherapy: A Case Report and a Review of the Literature.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
化生性乳腺癌（MpBC）是一种罕见的乳腺癌类型，以化疗反应欠佳、复发率高、预后差和治疗选择有限为特征。近期研究报告MpBC中程序性死亡配体1和TIL（肿瘤浸润淋巴细胞）高表达，提示免疫治疗（IO）在MpBC中可能有效。此外，多项报告已证实IO在MpBC中的活性。在本病例报告中，我们介绍了一例复发性MpBC患者，经atezolizumab（抗PD-L1）联合白蛋白结合型紫杉醇治疗后获得持久、快速的完全缓解，且即使在停止治疗后仍持续缓解。
展开英文摘要原文
Metaplastic breast cancer (MpBC) is a rare form of breast cancer known for suboptimal response to chemotherapy, high recurrence rate, poor prognosis, and limited treatment options. Recent studies have reported that MpBC has high expression of programmed death ligand 1 and tumor-infiltrating lymphocytes, indicating the potential effectiveness of immunotherapy (IO) in MpBC.
In addition, several reports have demonstrated the activity of IO in MpBC. In this case report, we present a case of recurrent MpBC that achieved durable, rapid, complete remission with atezolizumab (anti-PD-L1) and nab-paclitaxel with a continued response even after discontinued therapy.
论文信息
- 作者
- Al-Awadhi A、Alnaqbi S、Albawardi A
- 第一作者单位
- Department of Medical Oncology, Tawam Hospital, Al Ain, ARE.United States
- 通讯作者单位
- Department of Pathology, United Arab Emirates University, Al Ain, ARE.United Arab Emirates
- 文献类型
- 病例报告
- 期刊
- Cureus2024 Feb
- 原文标识
- PubMed 38314378 · DOI 10.7759/cureus.53419
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →